Royal Bank of Canada initiated coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a report published on Thursday, Briefing.com reports. The brokerage issued an outperform rating and a $25.00 target price on the stock. Several other equities analysts have also commented on FDMT. HC Wainwright restated a buy rating and set […]
StockNews.com cut shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Free Report) from a hold rating to a sell rating in a research report released on Tuesday morning. Several other research analysts have also weighed in on the stock. Stifel Nicolaus assumed coverage on shares of Aeglea BioTherapeutics in a report on Tuesday, July 25th. They set […]
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) was upgraded by equities researchers at SVB Leerink from a “market perform” rating to an “outperform” rating in a note issued to investors on Wednesday, Briefing.com reports. The brokerage presently has a $24.00 price objective on the stock. SVB Leerink’s price target would suggest a potential upside […]
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report)’s share price traded down 0.5% during mid-day trading on Tuesday . The stock traded as low as $1.98 and last traded at $2.03. 42,249 shares were traded during mid-day trading, a decline of 75% from the average session volume of 167,613 shares. The stock had previously closed […]
StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT – Free Report) in a research note published on Saturday. The firm issued a sell rating on the stock. Several other research analysts have also commented on DBVT. HC Wainwright reaffirmed a buy rating and issued a $10.00 price target on shares of DBV Technologies in […]